Influenza A virus H1N1 vaccine - Medicago

Drug Profile

Influenza A virus H1N1 vaccine - Medicago

Alternative Names: H1N1 VLP influenza vaccine - Medicago; Influenza A (H1N1) swine flu vaccine - Medicago; Influenza A H1N1 virus-like particle (VLP) vaccine - Medicago; Pandemic H1N1 virus vaccine - Medicago

Latest Information Update: 13 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medicago
  • Class Influenza A virus H1N1 vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza A virus H1N1 subtype

Most Recent Events

  • 03 Mar 2017 Phase-II development is ongoing in USA and Canada
  • 18 Sep 2013 Medicago has been acquired by Mitsubishi Tanabe Pharma Corporation
  • 11 Dec 2012 Medicago receives grant from National Research Council of Canada for Influenza VLP vaccine candidate development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top